Singapore markets closed

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
0.1529-0.0060 (-3.78%)
At close: 04:00PM EDT
0.1450 -0.01 (-5.17%)
Pre-market: 09:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1589
Open0.1608
Bid0.0000 x 0
Ask0.1538 x 100
Day's range0.1521 - 0.1638
52-week range0.0850 - 3.5900
Volume560,727
Avg. volume1,654,288
Market cap8.317M
Beta (5Y monthly)2.17
PE ratio (TTM)N/A
EPS (TTM)-1.3300
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.50
  • GlobeNewswire

    Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

    Company continues to evaluate strategic options to maximize shareholder valueMALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates. "As a result of last year’s FDA request for a

  • Simply Wall St.

    Galera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17

    The recent 19% drop in Galera Therapeutics, Inc.'s ( NASDAQ:GRTX ) stock could come as a blow to insiders who purchased...

  • GlobeNewswire

    Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

    FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended Se